Mary Caffrey

Authors found the pharmacy costs for momelotinib were $11,095 higher per month, too much to offset higher transfusion costs for ruxolitinib.

Symptomatic improvement on therapy for myeloproliferative neoplasms (MPNs) is very much based on the individual. Data does show momelotinib not only improved spleen size and anemia but also improved symptomatic burden.

Being married and having insurance can offer emotional support and financial stability to lead to early diagnosis and effective treatment, the authors found.

Therapy selection for younger patients with myeloproliferative neoplasms (MPNs) may be different based on the desire for fertility preservation, but they are also at greater risk of their disease progressing, explained Ruben Mesa, MD, FACP, of Atrium Health.

Experts are asking whether the study and treatment of myeloproliferative neoplasms (MPNs) is ready for a new era with new end points, with data that show how survival benefits are biologically linked to changes in the spleen, reduction in fibrosis, or other responses.

There can be a delay in diagnosis of myeloproliferative neoplasms as the symptoms of the diseases can be variable and common, such as fatigue, migraines, and difficulty concentrating, explained Ruben Mesa, MD, of Atrium Health.

A review of positions and track records of Vice President Kamala Harris and former President Donald Trump on reproductive health, the future of the Affordable Care Act, prescription drug costs, health care consolidation, and a proposed Medicare home health benefit.

Investigators added more data to an analysis first published in 2020 and got the same result: ruxolitinib beats other treatments for polycythemia vera.

Lalan Wilfong, MD, a 20-year medical oncologist with Texas Oncology, is senior vice president, value-based care, Thyme Care.

Attendees at the International Myeloma Society 21st Annual Meeting & Exposition got an early look at data for an investigational allogeneic chimeric antigen receptor (CAR) T-cell product from healthy donor cells to prevent graft-versus-host disease.

Ajai Chari, MD, covered both recent FDA approvals and pipeline products, such as non-BCMA chimeric antigen receptor (CAR) T-cell therapies and trispecifics, during a symposium on Immunotherapy at the International Myeloma Society 21st Annual Meeting & Exposition.

Investigators from Florida Cancer Specialists & Research Institute explored questions surrounding minimal residual disease (MRD) negativity testing in an abstract presented at the International Myeloma Society 21st Annual Meeting & Exposition.

The trial is seen as a complement to the MAIA trial, which had shown a significant overall survival benefit with daratumumab for patients with newly diagnosed multiple myeloma.

An oral session Friday at the International Myeloma Society 21st Annual Meeting & Exposition offered updates for the TRIMM-2 and RedirecTT-1 trials.

Anant Madabhushi, PhD, of Emory University, told attendees at the International Myeloma Society 21st Annual Meeting & Exposition how artificial intelligence's (AI) full potential in cancer care depends on its algorithms being validated by completed clinical trials.

A new consensus definition for high-risk myeloma patients and promising results from trials dedicated to their care may offer a "paradigm shift" in treatment, experts say at the International Myeloma Society 21st Annual Meeting & Exposition.

April's vote of the FDA Oncology Drug Advisory Committee to support use of MRD-negative CR as an end point for accelerated approval represents a triumph of science, persistence, and collaboration, said panelists at the International Myeloma Society 21st Annual Meeting & Exposition.

Speakers on precursor disease addressed distinctions between MGUS and smoldering multiple myeloma, risk stratification, and new thinking on the role of immunological aging, especially how it affects Black patients.

A study based on a decade's worth of Korean insurance data found that use of direct oral anticoagulants (DOACs) to address atrial fibrillation and venous thromboembolism in patients with myeloproliferative neoplasms (MPNs) is effective, with acceptable bleeding risk.

The 21st annual meeting of the International Myeloma Society (IMS) takes place September 25-28, 2024, in Rio de Janeiro, Brazil.

Researchers from Bulgaria conduct an analysis of the potential for therapeutic vaccines in by comparing testing results for patients from their country with an international data set.

Based on an Avalere Health report, Community Oncology Alliance warns that IRA negotiations could slice down payments needed to administer cancer drugs.

Inflammation and genetic mutations can drive cardiovascular complications in patients with myeloproliferative neoplasms, which include disorders such as polycythemia vera, essential thrombocythemia, and primary myelofibrosis.

A review by authors from China examines evidence involving different treatment approaches.

Attendees of the first Institute for Value-Based Medicine® regional event will hear top experts from Boston-area institutions speak about treating non–small cell lung cancer, targeting HER2 in breast cancer, and identifying biomarkers in sarcomas.

The annual meeting of oncology stakeholders presented by The American Journal of Managed Care® takes place September 12-13, 2024.